Kyverna Therapeutics, Inc.

Stage 4 · Declining · week 6

As of Oct 22, 2026, Kyverna Therapeutics is in Stage 4, the downtrend phase, now in week 6 (since Sep 16, 2026). It closed at $5.73, 49.1% below its 52-week high and below its 200-day average, which is falling.

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. More about the company

$5.73

-2.05% today

$354M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is KYTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-02-09 → 2026-10-22

S? 41w

S4 28w

S2 31w

2024-02-092026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 28w → S1 8w → S2 31w → S3 5w → S2 8w → S3 6w → S4 5w → S1 2w → S4 5w current

Total tracked: 140 weeks across 10 stage runs.

KYTX among Biotechnology245th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…245	KYTXKyverna Therapeutics, Inc.	Stage 4 · wk 6	40	−19.0%

vs 52W High

-49.1%

$5.67 lo$11.25 hi

49.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-29.9%

200 DMA: $8.18 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.60x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-19.0%

-22.7%

-36.0%

YTD

-34.7%

-19.7%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 0.60x

2026-10-21S4

Wk 6 · Vol 0.83x

2026-10-20S4

Wk 5 · Vol 0.89x

2026-10-19S4

Wk 5 · Vol 0.98x

2026-10-16S4

Wk 5 · Vol 0.85x

2026-10-15S4

Wk 5 · Vol 0.92x

2026-10-14S4

Wk 5 · Vol 1.54x

2026-10-13S4

Wk 4 · Vol 1.51x

2026-10-12S4

Wk 4 · Vol 0.51x

2026-10-09S4

Wk 4 · Vol 1.07x

2026-10-08S4

Wk 4 · Vol 1.62x

2026-10-07S4

Wk 4 · Vol 0.79x

Moving averages & range

50 DMA

$7.25

200 DMA

$8.18

52W High

$11.25

52W Low

$5.67

5D Low

$5.67

Resistance levels (recent highs)

20d High

$6.84

60d High

$8.95

120d High

$10.78

250d High

$11.25

Next resistance

+19.4%

to 20d High

ROE

-87.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.1

Kyverna Therapeutics: quick answers

What stage is Kyverna Therapeutics in?

As of Oct 22, 2026, Kyverna Therapeutics (KYTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Kyverna Therapeutics in an uptrend?

No. Kyverna Therapeutics is in a Stage 4 downtrend. It trades 29.9% below its 200-day average, which is falling.

How far is Kyverna Therapeutics from its 52-week high?

Kyverna Therapeutics closed at $5.73 on Oct 22, 2026, 49.1% below its 52-week high of $11.25. Its 52-week low is $5.67.

How has Kyverna Therapeutics performed over the past year?

As of Oct 22, 2026, Kyverna Therapeutics is down 19.7% over the past year and down 34.7% so far in 2026.

Which sector and industry is Kyverna Therapeutics in?

Kyverna Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.